Patents Assigned to Epigenomics AG
-
Patent number: 9017944Abstract: The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for predicting the disease free survival and/or response of a subject with a cell proliferative disorder of the breast tissues, to endocrine treatment.Type: GrantFiled: December 13, 2004Date of Patent: April 28, 2015Assignee: Epigenomics AGInventors: John Foekens, Nadia Harbeck, Thomas Koenig, Sabine Maier, John W. Martens, Fabian Model, Inko Nimmrich, Manfred Schmitt, Ralf Lesche, Dimo Dietrich, Volkmar Mueller, Antje Kluth Lukas, Ina Schwope, Oliver Hartmann, Peter Adorjan, Almuth Marx, Heinz Hoefler
-
Patent number: 8962246Abstract: Aspects of the present invention relate to compositions and methods for providing DNA fragments from an archived sample (e.g., paraffin-embedded and/or fixed-tissue biopsies, etc.). Particular aspects provide methods whereby high yields of DNA are isolated as well as a substantial portion of the DNA consists of long DNA fragments, and where the isolated genomic DNA is free of associated or cross-linked contaminants like proteins, peptides, amino acids or RNA. The methods are facile, cost-effective, and are characterized by high reproducibility and reliability. Particular aspects provide methods for providing DNA fragments derived from an archived sample, wherein the yield of DNA before, for example, an amplification step is at least 20%, and amplicons up to a length of about 1,000 base pairs are amplifiable.Type: GrantFiled: December 2, 2013Date of Patent: February 24, 2015Assignee: Epigenomics AGInventors: Matthias Ballhause, Kurt Berlin, Dimo Dietrich, Antje Kluth Lukas, Matthias Schuster, Ute Wagner, Reinhold Wasserkort, Heike Ziebarth
-
Publication number: 20150031021Abstract: The invention provides methods, nucleic acids and kits for determining the prognosis of a subject having cancer. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.Type: ApplicationFiled: July 9, 2012Publication date: January 29, 2015Applicant: EPIGENOMICS AGInventors: Joern Lewin, Manuel Krispin
-
Patent number: 8912129Abstract: Aspects of the present invention relate to the determination of the DNA methylation level at one or more CpG position within cells of a defined type in a tissue sample. This methylation level is deduced from the total DNA methylation level of all cells of the sample and from the content of said cells of interest. In aspects of the invention, the cell content is determined by means of histopatholoy, staining methods, antibodies, expression analysis or DNA methylation analysis.Type: GrantFiled: November 17, 2006Date of Patent: December 16, 2014Assignee: Epigenomics AGInventors: Joern Lewin, Kurt Berlin
-
Patent number: 8900829Abstract: Aspects of the invention provide methods, nucleic acids and kits for detecting, or for detecting and distinguishing between or among liver cell proliferative disorders or for detecting, or for detecting and distinguishing between or among colorectal cell proliferative disorders. Particular aspects disclose and provide genomic sequences the methylation patterns of which have substantial utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients.Type: GrantFiled: April 28, 2011Date of Patent: December 2, 2014Assignee: Epigenomics AGInventors: Juergen Distler, Thomas Hildmann, Ralf Lesche, Catherine Lofton-Day, Fabian Model, Matthias Schuster, Andrew Z. Sledziewski, Reimo Tetzner, Xiaoling Song
-
Publication number: 20140295445Abstract: Particular aspects provide methods for specific amplification of template DNA in the presence of potentially contaminating PCR products from previous amplification experiments. Particular embodiments comprise, in a first step, contacting DNA with a bisulfite solution, which sulfonates unmethylated (but not methylated) cytosines, resulting in cytosine deamination and generation of sulfonated uracil. Such sulfonation protects the template nucleic acid from being a target for the enzyme uracil-DNA-glycosylase (UNG), whereas any contaminating DNA, which contains unprotected unsulfonated or desulfonated uracils, is degraded enzymatically while the UNG is active. After UNG treatment and inactivation thereof, the sulfonated uracil bases are converted into uracil by desulfonation. Such aspects have substantial utility for decontamination of nucleic acid samples; e.g., for avoiding amplification of ‘carry over products’ in the context of DNA methylation analysis.Type: ApplicationFiled: June 13, 2014Publication date: October 2, 2014Applicant: EPIGENOMICS AGInventors: Reimo Tetzner, Dimo Dietrich
-
Publication number: 20140227700Abstract: The invention provides methods, nucleic acids and kits for detecting prostate cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.Type: ApplicationFiled: April 28, 2014Publication date: August 14, 2014Applicant: EPIGENOMICS AGInventors: Andrew Z. Sledziewski, Catherine E. Lofton-Day, Reimo Tetzner, Juergen Distler, Fabian Model, Shannon Payne, Dimo Dietrich
-
Patent number: 8771939Abstract: The present invention relates to a method for methylation analysis. It comprises the providing of a double stranded nucleic acid; its conversion, whereby unmethylated bases become distinguishable in their base-pairing behavior from methylated bases, and the analysis of both of the converted nucleic acid strands.Type: GrantFiled: August 1, 2007Date of Patent: July 8, 2014Assignee: Epigenomics AGInventors: Reimo Tetzner, Joern Lewin
-
Publication number: 20140179563Abstract: The invention provides methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders as well as therapy thereof by analysis of the gene EYA4 and its promoter and regulatory sequences. The invention further provides novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said gene as well as methods, assays and kits thereof.Type: ApplicationFiled: February 21, 2014Publication date: June 26, 2014Applicant: Epigenomics AGInventors: Peter Adorjan, Matthias Burger, Sabine Maier, Ralf Lesche, Susan Cottrell, Theo De Vos
-
Patent number: 8753810Abstract: Particular aspects provide methods for specific amplification of template DNA in the presence of potentially contaminating PCR products from previous amplification experiments. Particular embodiments comprise, in a first step, contacting DNA with a bisulfite solution, which sulfonates unmethylated (but not methylated) cytosines, resulting in cytosine deamination and generation of sulfonated uracil. Such sulfonation protects the template nucleic acid from being a target for the enzyme uracil-DNA-glycosylase (UNG), whereas any contaminating DNA, which contains unprotected unsulfonated or desulfonated uracils, is degraded enzymatically while the UNG is active. After UNG treatment and inactivation thereof, the sulfonated uracil bases are converted into uracil by desulfonation. Such aspects have substantial utility for decontamination of nucleic acid samples; e.g., for avoiding amplification of ‘carry over products’ in the context of DNA methylation analysis.Type: GrantFiled: February 19, 2010Date of Patent: June 17, 2014Assignee: Epigenomics AGInventors: Reimo Tetzner, Dimo Dietrich
-
Patent number: 8703414Abstract: The method according to the invention concerns in particular a method for the quantification of methylated DNA. For this purpose, the DNA to be examined is first transformed such that unmethylated cytosine is converted to uracil while 5-methylcytosine remains unchanged. Subsequently, the transformed DNA is amplified in the presence of a pair of real-time probes. For this, a probe is constructed, which is specific for the methylated or for the unmethylated state of the DNA, and a probe, which binds methylation-unspecifically to the amplificate. The ratio of the signal intensities of the probes or the CT values allows for the calculation of the degree of methylation of the examined DNA. The method according to the invention is suited particularly for the diagnosis and prognosis of cancer and other diseases associated with a change in the methylation status, as well as, prediction of adverse for side-effects of pharmaceuticals.Type: GrantFiled: July 20, 2006Date of Patent: April 22, 2014Assignee: Epigenomics AGInventor: Reimo Tetzner
-
Patent number: 8691503Abstract: The invention provides methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders as well as therapy thereof by analysis of the gene EYA4 and its promoter and regulatory sequences. The invention further provides novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said gene as well as methods, assays and kits thereof.Type: GrantFiled: February 13, 2003Date of Patent: April 8, 2014Assignee: Epigenomics AGInventors: Peter Adorjan, Matthias Burger, Sabine Maier, Ralf Lesche, Susan Cottrell, Theo De Vos
-
Publication number: 20140087449Abstract: Aspects of the present invention relate to compositions and methods for providing DNA fragments from an archived sample (e.g., paraffin-embedded and/or fixed-tissue biopsies, etc.). Particular aspects provide methods whereby high yields of DNA are isolated as well as a substantial portion of the DNA consists of long DNA fragments, and where the isolated genomic DNA is free of associated or cross-linked contaminants like proteins, peptides, amino acids or RNA. The methods are facile, cost-effective, and are characterized by high reproducibility and reliability. Particular aspects provide methods for providing DNA fragments derived from an archived sample, wherein the yield of DNA before, for example, an amplification step is at least 20%, and amplicons up to a length of about 1,000 base pairs are amplifiable.Type: ApplicationFiled: December 2, 2013Publication date: March 27, 2014Applicant: Epigenomics AGInventors: Matthias Ballhause, Kurt Berlin, Dimo Dietrich, Antje Kluth Lukas, Matthias Schuster, Ute Wagner, Reinhold Wasserkort, Heike Ziebarth
-
Patent number: 8679745Abstract: Aspects of the present invention relate to compositions and methods for providing DNA fragments from an archived sample (e.g., paraffin-embedded and/or fixed-tissue biopsies, etc). Particular aspects provide methods whereby high yields of DNA are isolated as well as a substantial portion of the DNA consists of long DNA fragments, and where the isolated genomic DNA is free of associated or cross-linked contaminants like proteins, peptides, amino acids or RNA. The methods are facile, cost-effective, and are characterized by high reproducibility and reliability. Particular aspects provide methods for providing DNA fragments derived from an archived sample, wherein the yield of DNA before, for example, an amplification step is at least 20%, and amplicons up to a length of about 1,000 base pairs are amplifiable.Type: GrantFiled: September 30, 2005Date of Patent: March 25, 2014Assignee: Epigenomics AGInventors: Matthias Ballhause, Kurt Berlin, Dimo Dietrich, Antje Kluth Lukas, Matthias Schuster, Ute Wagner, Reinhold Wasserkort, Heike Ziebarth
-
Patent number: 8623599Abstract: Aspects of the invention relate to composition and methods for the providing of DNA for methylation analysis that is in particular suitable to be applied in reference laboratories. Further 5 aspects of the invention relate to composition and methods for the highly specific and sensitive methylation analysis of the Septin 9 gene also in particular suitable to be applied in reference laboratories.Type: GrantFiled: June 6, 2008Date of Patent: January 7, 2014Assignee: Epigenomics AGInventors: Theo Devos, Cathy Lofton-Day, Andrew Sledziewski, Fabian Model, Michael Krouse, Jesse Ho, Matthias Schuster, Juergen Distler, Reimo Tetzner
-
Patent number: 8586302Abstract: The present invention relates to an improved method for the bisulfite conversion of DNA. In certain time-temperature ranges the efficacy of the bisulfite conversion is clearly improved. By combination with denaturating solvents, new reaction conditions and new purification methods the efficacy can be further increased The converted DNA can subsequently be analysed by different methods. The present invention facilitates the analysis of cytosine methylation.Type: GrantFiled: February 8, 2012Date of Patent: November 19, 2013Assignee: Epigenomics AGInventors: Ina Fuhrmann, Matthias Ballhause
-
Patent number: 8577615Abstract: The invention describes a method for the quantitative sequencing of nucleic acids treated with bisulfite. The invention particularly describes a method for the determination of the degree of methylation of a cytosine in the base sequence 5?-CG-3?, thus in a so-called CpG position, if the genomic sequence of the investigated DNA region is known. The invention makes possible the validation of sequence information in the sequencing of DNA treated with bisulfite. It is particularly described how the data obtained with conventional sequencing methods are first standardized with respect to their signal intensity, how the conversion rate of cytosine to uracil after bisulfite treatment is determined from these data, and how a correction factor can be determined with the help of this conversion rate, and this factor produces an essentially improved estimation of the degree of methylation actually present.Type: GrantFiled: June 5, 2003Date of Patent: November 5, 2013Assignee: Epigenomics AGInventors: Christian Piepenbrock, Jörn Lewin, Armin Schmitt
-
Publication number: 20130190205Abstract: Described is a method for detecting 5-methylcytosine in genomic DNA samples. First, a genomic DNA from a DNA sample is chemically converted with a reagent, 5-methylcytosine and cytosine reacting differently, and the pretreated DNA is subsequently amplified using a polymerase and at least one primer. In the next step, the amplified genomic DNA is hybridized to at least one oligonucleotide, forming a duplex, and said oligonucleotide is elongated by at least one nucleotide, the nucleotide carrying a detectable label, and the elongation depending on the methylation status of the specific cytosine in the genomic DNA sample. In the next step, the elongated oligonucleotides are analyzed for the presence of the label.Type: ApplicationFiled: February 21, 2013Publication date: July 25, 2013Applicant: Epigenomics AGInventors: Alexander Olek, Kurt Berlin
-
Publication number: 20120258454Abstract: The present invention relates to an improved method for the bisulfite conversion of DNA. In certain time-temperature ranges the efficacy of the bisulfite conversion is clearly improved. By combination with denaturating solvents, new reaction conditions and new purification methods the efficacy can be further increased The converted DNA can subsequently be analysed by different methods. The present invention facilitates the analysis of cytosine methylation.Type: ApplicationFiled: February 8, 2012Publication date: October 11, 2012Applicant: EPIGENOMICS AGInventors: Ina Fuhrmann, Matthias Ballhause
-
Patent number: 8257950Abstract: The present invention provides an improved method for the bisulfite conversion of DNA, and facilitates the analysis of cytosine methylation of genomic DNA. Novel combinations of denaturing solvents, new reaction conditions and new purification methods provide surprisingly efficacious methods for bisulfite conversion of DNA relative to prior art methods. The converted DNA may subsequently be analyzed by many different methods.Type: GrantFiled: June 13, 2011Date of Patent: September 4, 2012Assignee: Epigenomics AGInventors: Kurt Berlin, Matthias Ballhause, Karen Cardon